Improvement in symptom remission rate following robotic thymectomy in patients with myasthenia gravis.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 25 09 2019
revised: 13 01 2020
accepted: 16 01 2020
pubmed: 25 2 2020
medline: 22 12 2020
entrez: 25 2 2020
Statut: ppublish

Résumé

We investigated long-term symptom control of myasthenia gravis following robotic-assisted thoracic surgery (RATS) versus video-assisted thoracic surgery (VATS) thymectomy in a retrospective single-centre cohort. From 1999 to 2015, a total of 147 patients underwent thymectomy for myasthenia gravis. Demographic data, medications, operative details, hospital length of stay (LOS), procedure complications and follow-up data were collected by chart review. The Myasthenia Gravis Foundation of America classification was used to evaluate preoperative and postoperative myasthenia gravis status. The primary outcome was complete stable remission (CSR) status. Of the 147 patients, 86 (59%) patients underwent VATS thymectomy and 61 (42%) patients underwent RATS thymectomy. There was no operative mortality. The median follow-up was 12 years in the VATS group [interquartile range (IQR) 9-14 years] and 5 years in the RATS group (IQR 3-6 years) (P = 0.001). Two patients in the VATS (2%) and 2 patients (3%) in the RATS group had Clavien-Dindo grade 3 complications. The median LOS was 3 days in the VATS group (IQR 2-4 days) and 2 days in the RATS group (IQR 2-3 days) (P = 0.013). The rate of CSR was 18% (14/65) in the VATS group compared to 26% (16/44) in the RATS group (P = 0.06). Younger age, RATS approach and preoperative medical remission were independently predictive of CSR by Cox regression analysis. Patients who underwent RATS thymectomy and were younger or medically remitted before surgery were more likely to achieve CSR. Both methods yield excellent perioperative outcome.

Identifiants

pubmed: 32091092
pii: 5753902
doi: 10.1093/icvts/ivaa021
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

827-833

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Juha Kauppi (J)

Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.

Sari Atula (S)

Department of Neurology, Helsinki University Hospital, Helsinki, Finland.

Daniel Strbian (D)

Department of Neurology, Helsinki University Hospital, Helsinki, Finland.

Eric Robinson (E)

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Hanni Alho (H)

Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.

Eero Sihvo (E)

Department of Surgery, Central Finland Central Hospital, Jyväskylä, Finland.

Ilkka Ilonen (I)

Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.

Jari Räsänen (J)

Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH